Merck Sharp & Dohme Llc

This early-stage study tests a new vaccine called V540D that may protect against more types of HPV than current vaccines. HPV can cause certain cancers, and this vaccine is designed to cover additional virus types. The study involves 72 healthy adults and focuses on safety and ho…

This phase 3 study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer getting worse. About 340 participants who have already tried hormone therap…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given with chemo) to the standard IV version for adults in Japan with metastatic non-small cell lung cancer who haven't had treatment before. The main goal is to see if the shot provides similar drug lev…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with advanced esophageal cancer live longer or delay the cancer from coming back. About 700 participants who cannot have surgery will receive either pembrolizum…

This early-stage study tests an oral drug called MK-1026 (nemtabrutinib) in 12 Chinese adults with blood cancers like lymphoma or leukemia that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, an…

This study tests a new once-daily pill (doravirine/islatravir) for adults with HIV who have never taken HIV medication before. About 537 participants will receive either the new pill or a standard combination pill to see how well they control the virus and if side effects differ.…

This study tests whether switching to a once-daily pill containing doravirine and islatravir works as well as staying on current HIV medications for people whose virus is already suppressed. About 550 adults with HIV-1 took part. The goal is to see if the new pill keeps the virus…

This study tests whether adding either belzutifan or quavonlimab to a standard two-drug therapy (pembrolizumab and lenvatinib) helps people with advanced clear cell renal cell carcinoma live longer or keep their cancer from growing. About 1,650 adults who have not had prior treat…

This study tests whether a new once-weekly pill (ISL+ULO) can keep HIV under control as well as a standard daily pill (BIC/FTC/TAF). About 150 adults with already-suppressed HIV will switch to the weekly treatment or stay on their daily regimen. Researchers will measure how many …

This study tests whether adding the immunotherapy drug pembrolizumab before and after surgery can help people with advanced head and neck cancer live longer without their cancer coming back. About 714 participants with stage III or IVA disease will receive either pembrolizumab pl…

This study compares a new drug, MK-2870, to standard chemotherapy (docetaxel or pemetrexed) in 556 adults with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations or others). The goal is to see if MK-2870 can slow cancer growth and help people li…

This study tests whether adding sacituzumab govitecan to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 614 participants will receive either the c…

This early-stage study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the dr…

This study tests a new drug, MK-2140, alone or with other treatments, in people with certain B-cell blood cancers that have come back or not responded to prior therapy. About 223 adults with mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or Richter trans…

This phase 3 trial tests whether a new drug combination (belzutifan + lenvatinib) works better than the current standard drug (cabozantinib) for people with advanced kidney cancer that has gotten worse after prior treatment. About 747 participants will be enrolled. The study meas…

This study compares a new oral drug, nemtabrutinib, against standard chemotherapy combinations for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a specific genetic change (TP53 mutation). About 300 particip…

This study tested whether giving the immunotherapy drug pembrolizumab after surgery could delay melanoma from returning in people with high-risk stage III melanoma. About 1,000 participants were randomly assigned to receive either pembrolizumab or a placebo for up to a year. The …

This study tests whether adding the drug pembrolizumab to standard chemotherapy can help children and young adults with Hodgkin lymphoma whose cancer did not shrink enough after initial treatment. About 340 participants will receive the combination therapy. The goal is to see if …

This study tests a new drug, MK-2870, against standard treatments for people with advanced stomach, esophageal, or gastroesophageal junction cancer that has not responded to earlier therapies. About 450 participants will be randomly assigned to receive either MK-2870 or a treatme…

This large Phase 3 study tests an oral medication called MK-0616 in about 14,550 people at high risk for heart problems due to hardened arteries or high cholesterol. The goal is to see if taking this pill daily can delay or prevent major events like heart attacks, strokes, or eme…

This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in people with advanced kidney cancer that has worsened after at least two prior treatments. The goal is to see if the combo is safe and can better control the disease. About 60 adults …

This study tests an injectable form of the cancer drug pembrolizumab (Keytruda) in 66 adults whose Hodgkin lymphoma or primary mediastinal B-cell lymphoma has returned or not responded to prior treatment. The main goals are to measure how much drug gets into the body and how many…

This study tests a new medicine, raludotatug deruxtecan, in 160 people with advanced gastrointestinal cancers like pancreatic, bile duct, colorectal, stomach, or gastroesophageal junction cancer. The drug is designed to attach to cancer cells and deliver a treatment that destroys…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent kidney cancer from returning after surgery. About 272 people with high-risk kidney cancer will receive either the vaccine plus immunotherapy or a place…

This study tested the drug pembrolizumab in over 1,600 people with various advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink or control the tumors. The trial focused on identifying which patients were most likel…

This study tests a new drug called MK-2870 against standard chemotherapy for people with endometrial cancer who have already tried platinum-based chemo and immunotherapy. About 710 participants will receive either MK-2870 or a doctor-chosen chemo. The goal is to see if MK-2870 he…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent melanoma from coming back in people with high-risk stage II-IV melanoma. About 1,089 participants who have had their melanoma surgically removed will re…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given under the skin) to the standard IV version, both combined with chemotherapy, for people with advanced non-small cell lung cancer that hasn't been treated before. About 377 adults will take part to …

This study tests whether combining two drugs, olaparib and pembrolizumab, can shrink or control advanced solid tumors that have certain DNA repair problems. About 300 adults whose cancer has not responded to standard treatments will take part. The goal is to see if this combinati…

This study tests a new drug called MK-7240 (tulisokibart) in about 1020 people with moderate-to-severe ulcerative colitis. The goal is to see if it can help patients achieve and maintain remission (fewer symptoms and healed gut lining) compared to a placebo. Participants will be …

This study tests an experimental drug called MK-5475 (frespaciguat) in 129 adults who have high blood pressure in the lungs caused by chronic lung disease (COPD). The main goal is to see if the drug helps people walk farther in 6 minutes after 24 weeks compared to a placebo. The …

This study looks at the long-term safety and effectiveness of the drug MK-0616 (enlicitide decanoate) in adults with high cholesterol. It includes 3000 people who already completed an earlier study with the same drug. The main goals are to track side effects and see how well the …

This study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a painful skin condition. Participants receive either the drug or a placebo to see if it reduces abscesses and inflammation by at least half after 16 weeks. The goal is…

This study tests whether adding either of two investigational drugs (favezelimab or vibostolimab) to the standard combination of pembrolizumab and enfortumab vedotin works better than the standard combination alone for people with advanced bladder cancer that has spread. About 39…

This study tests whether the immunotherapy drug pembrolizumab works better than standard chemotherapy for women with a certain type of advanced or returning endometrial cancer (dMMR). About 280 women who have not had chemotherapy before will take part. The goal is to see if pembr…

This phase 3 study tests whether adding belzutifan (a pill) to standard pembrolizumab (an IV drug) can better prevent kidney cancer from returning after surgery. About 1,800 adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence will receive e…

This study is for people with advanced melanoma that hasn't been treated yet. Researchers are testing whether adding other drugs to pembrolizumab (an immunotherapy) can shrink tumors or stop them from growing. The study involves about 315 participants and focuses on safety and ho…

This study tests a new drug combination (pembrolizumab plus berahyaluronidase alfa) given as a shot under the skin for Japanese patients with advanced squamous cell skin cancer that has come back, spread, or cannot be removed with surgery. The main goal is to see if the treatment…

This study aimed to test whether adding the experimental drug boserolimab to standard treatment (pembrolizumab and chemotherapy) before surgery could help people with high-risk, early-stage triple-negative breast cancer. The goal was to see if the combination was safe and could e…

This study is for people with advanced bladder cancer that has spread or cannot be removed by surgery. It tests a combination of two or three drugs (MK-2870, enfortumab vedotin, and pembrolizumab) to see if they are safe and can shrink tumors. The trial has two parts: first check…

This study tests whether a new under-the-skin injection of the immunotherapy drug pembrolizumab works as well as the standard IV infusion for people with advanced non-small cell lung cancer. About 67 participants will receive either the shot or the IV, and researchers will measur…

This study tests if adding a new drug (belzutifan) or a different immunotherapy combo (MK-1308A) to standard treatment helps people with advanced clear cell kidney cancer live longer or slow their cancer. About 249 Chinese adults who have not had prior treatment for advanced dise…

This study tests an experimental drug called efinopegdutide in 80 adults with liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can lower liver fat, inflammation, and scarring compared …

This study looks at the long-term safety of a medicine called sotatercept for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 130 adults who completed a previous study will receive weight-based doses of sotatercept …

This early-stage study is testing a new under-the-skin injection of the cancer drug pembrolizumab in 72 adults with advanced solid tumors. The goal is to see how well the body absorbs the drug and to check for side effects. Participants receive one of two different doses. This is…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants will receive either pembrolizumab or a placebo along…

This study tests experimental drug combinations for people with advanced clear cell renal cell carcinoma (a type of kidney cancer) who have not received prior treatment. The goal is to check safety and how well the combinations shrink tumors. About 400 participants will be enroll…

This study tests whether adults with HIV who are already well-controlled on a standard three-drug pill can safely switch to a new two-drug pill (DOR/ISL) taken once daily. About 514 participants will be randomly assigned to either continue their current medication or switch to th…

This study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps people with high-risk bladder cancer that hasn't spread into the muscle. About 1,400 participants receive either BCG alone or BCG plus pembrolizumab. The goal is to see if the com…

This study tests whether adding lenvatinib to standard pembrolizumab plus chemotherapy helps people with metastatic esophageal cancer live longer. About 864 participants will receive either the three-drug combo or the standard two-drug treatment. The goal is to see if the new com…

This study tests a new combination of two immunotherapy drugs (MK-1308A) against other treatments for people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if the new combo can shrink tumors or slow the disease. About 302 adults with stage IV …

This study is for people with advanced kidney cancer that has gotten worse after initial treatment. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 370 participants will receive experimental treatments, and researchers will monitor side eff…

This study tests a daily pill called olaparib in people with advanced cancers that have not responded to standard treatments. It focuses on tumors with specific DNA repair flaws (HRRm or HRD). The goal is to see if the drug can shrink tumors and control the disease. About 326 adu…

This study is for adults with HIV who have already been taking a higher-dose combination pill (DOR/ISL) in earlier studies. Researchers want to see if a lower-dose version is safe and still controls the virus over 96 weeks. About 641 participants will take the new pill once daily…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian tube, or …

This study tests an experimental drug called zilovertamab vedotin in about 140 people whose diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. Re…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can keep bladder cancer from coming back after surgery. About 230 people with high-risk muscle-invasive bladder cancer will receive either the vaccine plus immunotherapy o…

This early-stage trial tests a new drug, MK-2870, alone or with pembrolizumab (with or without chemotherapy) in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 participants will be enrolled.

This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in about 45 Chinese adults with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety and how the body processes the drugs. This …

This study allows people with HIV-1 who benefited from the two-drug combination doravirine/islatravir in earlier trials to continue receiving it. The main goal is to monitor the long-term safety and side effects of this treatment. It is open to about 2000 participants who are alr…

This study looks at whether people with certain cancers prefer getting the drug pembrolizumab as a shot under the skin instead of through an IV. About 147 participants will try both methods and report which they like better. The goal is to see if the shot is a more convenient opt…

This study tests whether adding MK-1167 to standard Alzheimer's medication can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. The main goals are to see if the drug imp…

This early-stage study tests a new medicine called MK-2828 in 64 people with type 2 diabetes. The main goal is to check if it is safe and well-tolerated. Researchers will also measure how the drug moves through the body and whether it lowers a marker of inflammation (hsCRP). This…

This early-stage study is testing two different versions of MK-1167, an experimental medicine being developed for Alzheimer's disease, in 16 healthy adults. The main goal is to see how the drug moves through the body and to check its safety before testing it in people with Alzhei…

This early-stage study in 60 healthy adults checks whether a single tablet containing enlicitide and rosuvastatin delivers the same drug levels as taking the two medicines separately. Participants will provide blood samples to measure how much of each drug gets into the body over…

This study looks at how a common heart medicine (diltiazem) changes the amount of nemtabrutinib in the blood of 24 healthy adults. Participants take nemtabrutinib with and without diltiazem, and researchers measure drug levels over time. The goal is to understand potential drug i…

This study looks at how enlicitide (MK-0616) enters the bloodstream when taken as different tablet forms. Thirty healthy adults will take the drug and have blood samples taken to measure absorption. Researchers will also check for side effects and how well the drug is tolerated.